Paul Tudor Jones's IOVA Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 216,004 shares of Iovance Biotherapeutics, Inc. (IOVA) worth $758,174, representing 0.00% of the portfolio. First purchased in 2017-Q3, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in IOVA, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 211,468 shares. Largest reduction occurred in Q4 2024, reducing 218,927 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Iovance Biotherapeutics (IOVA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Iovance Biotherapeutics (IOVA) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +36,510 | Add 20.34% | 216,004 | $3.51 |
| Q4 2025 | +57,750 | Add 47.44% | 179,494 | $2.73 |
| Q3 2025 | +121,744 | New Buy | 121,744 | $2.17 |
| Q2 2025 | -122,930 | Sold Out | 0 | $0.00 |
| Q1 2025 | +122,930 | New Buy | 122,930 | $3.33 |
| Q4 2024 | -218,927 | Sold Out | 0 | $0.00 |
| Q3 2024 | -80,958 | Reduce 27.00% | 218,927 | $9.39 |
| Q2 2024 | +55,269 | Add 22.59% | 299,885 | $8.02 |
| Q1 2024 | +211,468 | Add 637.95% | 244,616 | $14.82 |
| Q4 2023 | +33,148 | New Buy | 33,148 | $8.13 |
| Q3 2023 | -115,277 | Sold Out | 0 | $0.00 |
| Q2 2023 | +57,750 | Add 100.39% | 115,277 | $7.04 |
| Q1 2023 | -37,102 | Reduce 39.21% | 57,527 | $0.01 |
| Q4 2022 | +15,849 | Add 20.12% | 94,629 | $0.01 |
| Q3 2022 | -11,714 | Reduce 12.94% | 78,780 | $9.58 |
| Q2 2022 | +60,124 | Add 197.97% | 90,494 | $11.04 |
| Q1 2022 | -57,162 | Reduce 65.30% | 30,370 | $16.66 |
| Q4 2021 | +39,550 | Add 82.43% | 87,532 | $19.09 |
| Q3 2021 | +47,982 | New Buy | 47,982 | $24.66 |
| Q2 2021 | -150,091 | Sold Out | 0 | $0.00 |
| Q1 2021 | +150,091 | New Buy | 150,091 | $31.66 |
| Q3 2020 | -31,938 | Sold Out | 0 | $0.00 |
| Q2 2020 | +31,938 | New Buy | 31,938 | $27.46 |
| Q4 2017 | -19,000 | Sold Out | 0 | $0.00 |
| Q3 2017 | +19,000 | New Buy | 19,000 | $7.74 |
Paul Tudor Jones's Iovance Biotherapeutics Investment FAQs
Paul Tudor Jones first purchased Iovance Biotherapeutics, Inc. (IOVA) in Q3 2017, acquiring 19,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Iovance Biotherapeutics, Inc. (IOVA) for 25 quarters since Q3 2017.
Paul Tudor Jones's largest addition to Iovance Biotherapeutics, Inc. (IOVA) was in Q1 2024, adding 244,616 shares worth $3.63 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 216,004 shares of Iovance Biotherapeutics, Inc. (IOVA), valued at approximately $758,174.
As of the Q1 2026 filing, Iovance Biotherapeutics, Inc. (IOVA) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Iovance Biotherapeutics, Inc. (IOVA) was 299,885 shares, as reported at the end of Q2 2024.